Big Study Upends Antidepressant Rankings

Woman holding a white pill and a glass of water
Photo: fizkes / Shutterstock

A massive review of over 30,000 patients just named three antidepressants that may keep people well longer than one of the most prescribed drugs on the market.

Quick Take

  • Researchers reviewed 115 clinical trials with more than 30,000 participants to compare antidepressants head-to-head.
  • Escitalopram, duloxetine, and agomelatine showed a better chance of sustained response than fluoxetine.
  • People on escitalopram or duloxetine were also less likely to quit their trials early.
  • Researchers call the findings promising but say they are “far from definitive.”

What The Study Actually Found

Scientists pulled together 115 randomized controlled trials for this review, covering more than 30,000 patients total. Instead of only comparing drugs against sugar pills, 35 of those trials pitted one antidepressant directly against another. That head-to-head approach let researchers rank drugs against each other, not just against doing nothing.

Three names stood out. Escitalopram, duloxetine, and agomelatine all showed a stronger chance of keeping patients well compared to fluoxetine, one of the most commonly prescribed antidepressants in the world. On top of that, people taking escitalopram or duloxetine stuck with their treatment longer. Fewer of them dropped out of the studies compared to those on fluoxetine.

Why Sustained Response Matters More Than A Quick Fix

Depression treatment isn’t just about feeling better for a few weeks. The real goal is staying well. A drug that helps someone feel better for a month but fails by month four isn’t solving the problem. That’s why this review focused on sustained response instead of short bursts of improvement, giving doctors a more useful measure of what actually works over time.

Patient dropout numbers matter too, even though they’re an imperfect stand-in for effectiveness. If people keep taking a medicine, it often means they’re tolerating it well and feel it’s working. Escitalopram and duloxetine scoring better here adds a practical layer to the findings. A drug that works on paper doesn’t help anyone if patients quit taking it.

The Honest Limits Behind The Headline

The researchers themselves pumped the brakes on big claims. More than half the studies in the main analysis carried a high risk of bias, meaning flaws in design or reporting could skew results. That’s a serious caveat, and it’s worth sitting with before anyone changes their prescription based on this alone.

The term “long term” also deserves a second look. Most of the head-to-head trials only tracked patients for around six months. Just six of the 115 trials followed people longer than that. Six months is useful information, but it’s not the same as knowing how these drugs compare over five or ten years of real-world use.

It’s also important to remember the comparison was against fluoxetine specifically, not against every antidepressant on the shelf. Escitalopram, duloxetine, and agomelatine beating one commonly used drug doesn’t mean they’re the best choice for every patient or every condition. Depression treatment is personal, and what works for one person can fail for another regardless of what a large study finds on average.

How This Fits The Bigger Picture On Antidepressants

This isn’t the first time researchers have found that antidepressants perform similarly in head-to-head efficacy during short-term treatment. A 2007 review of 293 studies found no major efficacy differences among 12 common antidepressants, though it did find differences in side effects. That history makes this new review’s long-term angle notable, but it also means sweeping claims should be held loosely until more data comes in.

Other prior research has raised separate questions about antidepressants and quality of life over time, with one study finding no clear improvement in overall physical or mental health among long-term users. None of that contradicts this new review’s narrow finding about sustained response. It simply shows depression treatment research is still filling in gaps, and no single study closes the book on which drug is truly best.

What Comes Next

For now, the honest takeaway is this: escitalopram, duloxetine, and agomelatine showed real advantages over fluoxetine in keeping people well, based on solid trial data. But the six-month window and bias concerns mean doctors and patients should treat this as a strong lead, not a final verdict. Anyone on antidepressants should talk with their doctor before making changes, since individual response varies far more than any averaged study can capture.

Sources:

sciencedaily.com